CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia (Poly-CO)

CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia: a Multicentric Study. Co-Rebreathing for the Measurement of Total Red Cell Mass in Polycythemia.

The optimized CO-Rebreathing is an efficient method to evaluate the red cell mass and has been used in the vast majority of studies in sport medicine. However, this method has never been evaluated on a large scale in the diagnosis of primitive or secondary polycythemia. The standard procedure to evaluate the red cell mass is based on isotopic measurement using Cr51-labelled red cells, but its lack of availability in many centers highlights the need for a non-invasive and rapid alternative method. The purpose of this study is to evaluate and validate the CO-Rebreathing method in this set of indications.

Study Overview

• Status: Completed
• Conditions: Polycythemia
• Intervention / Treatment: Other: CO-Rebreathing technique at diagnosis of polycythemia

Detailed Description

The definition of a true polycythemia is stricto sensu an increased red cell mass (RCM) above 125% of the expected value depending on the size and the weight of the patient. However, this measurement requires an isotopic labeling of red cells and is not available in most of the hospitals. Therefore, the diagnosis of polycythemia, and particularly Polycythemia Vera (PV) is based on routine red blood cells parameters, i.e. hemoglobin level and hematocrit. If these parameters are efficient in marked polycythemia, discrepancies have been observed in milder cases. Two situations where a RCM evaluation is particularly required can be described:

• In patients with a hematocrit level between 52 and 60% (men) or between 48 and 56% (women) in order to limit invasive investigations to patients with a confirmed polycythemia diagnosis
• In JAK2V617F positive myeloproliferative neoplasms (MPN) with hematocrit and hemoglobin levels under the PV cut-off in order to discriminate between masked PV and essential thrombocythemia CO-Rebreathing is a fast, non invasive alternative method for RCM evaluation. It is based on the high affinity of carbon monoxide (CO) for hemoglobin. The decrease in the HbCO percentage after CO inhalation is dependent on the total hemoglobin mass from which RCM can be obtained. The investigators propose a tri-centric study evaluating CO-Rebreathing as an alternative tool to measure RCM in the diagnosis of polycythemia in the two categories of patients described above.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Loïc GARCON, professor; Phone Number: +33 322 087 056; Email: garcon.loic@chu-amiens.fr
• Study Contact Backup: Name: Mohamed AIT AMER MEZIANE, Phd; Phone Number: +33 322 088 384; Email: aitamermeziane.mohamed@chu-amiens.fr

Study Locations

• France
  • Picardie
    • Amiens, Picardie, France, 80054
      • CHU Amiens Picardie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adult patient
2. Informed consent obtained

3. Requirement of an isotopic red cell mass determination:

   a - Hematocrit between 52 and 60% (men) or 48 and 56% (women) with no argument for a PV (JAK2V617F negative, EPO level normal/high).

   b - Patients with a JAK2V617F positive MPN and a hematocrit level between 46 and 50% (women) or 48 and 52% for men.

4. No recent vascular event (<6 mois)
5. No unstable coronaropathy
6. Non smoking since 24 hours.
7. ECOG <2
8. Negativity of pregnancy test/effective contraception for childbearing age women,
9. Health insurance

Exclusion Criteria:

1. Recent venous event <1 months, cerebral stroke < 6 mois)
2. Evolutive cardiopathy (< 6 months)
3. Chronic Respiratory failure
4. Smokers with no withdrawal in the last 24 hours before CO-Rebreathing
5. Basal HbCO>7% the day of CO-Rebreathing
6. Pregnant or breast feeding women
7. Patient enable to give an informed consent
8. Inclusion in an interventional clinical trial in the last three months.
9. Any contraindication to lung function testing

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CO-Rebreathing; The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.	Other: CO-Rebreathing technique at diagnosis of polycythemia; The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
equivalence of RCM determination by CO-Rebreathing in comparison to the traditional isotopic measurement in the diagnosis of polycythemia	The primary outcome is to prove the equivalence of RCM determination by CO-Rebreathing in comparison to the traditional isotopic measurement in the diagnosis of polycythemia.	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AE / SAE / EI	Incidence, grade type according to NCI-CTCAE v4.0	1 month
Cumulative incidence of thrombotic and hemorrhagic complications	Cumulative incidence of thrombotic and hemorrhagic complications List according to PT1 protocol.	1 month
Deaths and causes	Deaths and causes	1 month
Analysis of the results of VGTCO and VGTi	Analysis of the results of VGTCO and VGTi as a function of hemoglobin and hematocrit	1 month

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens
• Investigators: Study Director: Loïc GARCON, professor, CHU Amiens-Picardie; Principal Investigator: Lydia ROY, Doctor, CHU Henri Mondor, France; Principal Investigator: Marjolaine GEORGES, Doctor, Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2019
• Primary Completion (Actual): May 1, 2020
• Study Completion (Actual): May 1, 2020

Study Registration Dates

• First Submitted: December 1, 2016
• First Submitted That Met QC Criteria: December 30, 2016
• First Posted (Estimate): January 2, 2017

Study Record Updates

• Last Update Posted (Estimate): January 19, 2023
• Last Update Submitted That Met QC Criteria: January 17, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: myeloproliferative neoplasms; Polycythemia; CO-Rebreathing; red cell mass determination
• Additional Relevant MeSH Terms: Hematologic Diseases; Polycythemia
• Other Study ID Numbers: PI2016_843_0032

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No